The Transient Receptor Potential Cation Channel Subfamily M Member 8 pipeline drugs market research report outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily M Member 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Transient Receptor Potential Cation Channel Subfamily M Member 8 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Ophthalmology, Genito Urinary System, and Undisclosed which include the indications Pain, Ocular Pain (Eye Pain), Keratoconjunctivitis Sicca (Dry Eye), Overactive Bladder, and Unspecified. It also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily M Member 8 targeted therapeutics development with respective active and dormant or discontinued products.
The Transient Receptor Potential Cation Channel Subfamily M Member 8 pipeline targets constitutes close to 12 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, and Preclinical stages are 1, 1, 3, 1, and 5 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Transient Receptor Potential Cation Channel Subfamily M Member 8 overview
Transient receptor potential cation channel subfamily M member 8 (TRPM8), also known as the cold and menthol receptor 1 (CMR1), is a protein that in humans is encoded by the TRPM8 gene. This receptor involved in calcium ion transmembrane transport and positive regulation of cold-induced thermogenesis.
For a complete picture of Transient Receptor Potential Cation Channel Subfamily M Member 8’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
